companydata.dkSalient Pharma ApS: Financial statements 2019
CVR: 36900709
Salient Pharma ApS (CVR 36900709) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK -729,822 and a net result of DKK -2,359,834 compared with DKK -710,176 the year before. Equity amounted to DKK 409,647. The solvency ratio was 70.8%. The company had 1 employee in the financial year.
- Gross Profit
- -729,822 kr.
- Profit/Loss
- -2,359,834 kr.
- Equity
- 409,647 kr.
- Total Assets
- 578,899 kr.
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | -730 t. | -2.4 mio. | 410 t. | 1 |
| 2018 | - | -838 t. | -710 t. | 2.8 mio. | - |
| 2017 | - | -1.2 mio. | -971 t. | -1.8 mio. | - |
| 2016 | - | -955 t. | -772 t. | -847 t. | - |
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2019
Salient Pharma ApS has published its annual report for 2018. Gross profit came to DKK -837,788, and the net result was DKK -710,176.
About Salient Pharma ApS
Salient Pharma ApS is a Danish company of the type Anpartsselskab based in Glostrup, founded in 2015. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Ulrik Spork. The company is owned by HB-MEDICAL HOLDING ApS, CAND.PHARM. POVL M. ASSENS FOND and SPORCON LIFESCIENCE ADVISORS ApS. In 2025, the company reported a gross profit of DKK -129,889 and a net result of DKK -218,345 compared with DKK -202,180 the year before. Equity amounted to DKK -1,344,010.